Sentiment Summary
Recent Events
Q2 2026 earnings release on 2026-08-26 is scheduled.
Boston Scientific's Q2 2026 earnings release and conference call is scheduled for 2026-07-29.
The Q2 2026 earnings release and conference call are set for 2026-07-23; analysts forecast a price impact of at least 1% as investors react to the quarterly performance is expected.
Abbott Laboratories second quarter 2026 earnings release on 2026-07-17. Low importance estimated as a routine scheduled announcement scheduled.
Annual dividend ex-date for CHF 4.70 per share on June 19, 2026, as proposed on May 18, 2026. The dividend is scheduled for payment on June 23, 2026. A low positive impact is estimated as dividends provide direct value to shareholders, scheduled.
Annual General Meeting 2026 scheduled for June 16, 2026, where shareholders will vote on proposals including the annual dividend. A neutral impact is estimated as this is a standard governance procedure, scheduled.
Annual General Meeting to vote on director re-elections and a general mandate for share issuance on June 10, 2026, scheduled.
Company executives are scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference on 2026-06-08; Low importance is estimated as conference presentations typically result in minimal immediate price movement, scheduled.
Medtronic to report financial results for its fourth quarter and full fiscal year 2026 on June 3, 2026, scheduled. High importance is estimated due to typical high volatility surrounding annual earnings releases.
Annual General Meeting to approve FY2025 dividends and auditor changes scheduled for May 28, 2026; Low importance justified by the expected approval of standard corporate items.
The company's board will meet to approve and announce the unaudited first quarter results for the three months ended March 31, 2026, on May 27, 2026; quarterly earnings releases typically result in moderate price volatility of 5-10%, scheduled.
Quarterly dividend increased by 3.1% to $1.34 per share. The ex-dividend date is May 26, 2026. A price impact of ≥1% is estimated as dividend increases typically have a modest positive effect, scheduled.
Partner Merck (MSD) announcement that the Phase 3 study of sacituzumab tirumotecan (sac-TMT/MK-2870) for advanced endometrial cancer met its primary endpoints of OS and PFS; High importance estimated due to potential for >10% price impact as a core asset success scheduled
The HARMONi-6 study for Ivonescimab was selected for a Plenary Session presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) annual meeting, indicating high potential clinical impact. Estimated price impact ≥5% due to the prestige of the session. Scheduled.
Announced positive results on 2026-05-19 from the FRACTURE pivotal trial for its SEISMIQ 4CE Coronary Intravascular Lithotripsy (IVL) Catheter, meeting primary safety and effectiveness endpoints.
NMPA approval for ω-3 Triglycerides/Fat Emulsion/Amino Acids/Glucose injection on May 19, 2026, scheduled. Low importance is estimated as this is a routine product approval for a non-core therapy.
IDC report released on May 19, 2026, confirmed SenseTime as the leader in China's visual AI market for the tenth consecutive year in 2025.
Announced a discloseable transaction on 2026-05-19 regarding the aggregated purchase of wealth management products totaling 488 million RMB over 12 months. Low importance is estimated as this is a routine cash management activity using idle funds.
On 2026-05-18, the company announced a plan to utilize up to US$100 million in internal funds for on-market share purchases for its employee share schemes; a 5-10% price impact is expected as the move signals management's belief that the shares are undervalued.
Announced adjustment of R&D pipeline on 2026-05-18, terminating development of two ADC drug candidates (RC88, RC108) and reallocating funds to the PD-1/VEGF bispecific antibody project RC148. Medium importance is estimated due to the strategic focus on more promising assets.
Announced a $1.5 billion investment on 2026-05-18 for an approximately 34% equity stake in MiRus LLC, with an exclusive option to acquire its TAVR business for an additional $3 billion.
Announced a leadership transition in its Neuroscience Portfolio on May 18, 2026. Brett Wall will depart, with Dr. Kweli Thompson taking over effective June 1, 2026. Medium importance is estimated as executive changes can influence strategic direction.
Announced full-year 2025/26 results, reporting sales growth of 5.9% and a normalized EBITA increase of 17.3% in local currencies, in line with guidance.
The company announced that its highly selective KAT6 inhibitor, SYH2095 tablets, received clinical trial approval in China for treating advanced malignant tumors on May 18, 2026; such approvals typically have a minor price impact of 1-5%, expected.
Presented positive Phase 1b clinical trial results for IBI3002 in asthma at the 2026 ATS conference on 2026-05-18. This early clinical success is estimated to result in a >=1% price impact, expected.
Announced a $2 billion accelerated share repurchase (ASR) agreement on 2026-05-18, part of a previously authorized $5 billion plan. The final settlement is expected by June 30, 2026.
Announced promising Phase 1 data for HS-20118, an oral IL-23R antagonist for psoriasis, at the SID 2026 meeting. Price impact is estimated at 1-5% as Phase 1 data is early-stage scheduled.
Announced positive results from a Phase II trial of Ligufalimab (anti-CD47) combination therapy for frontline Acute Myeloid Leukemia (AML), published at the EHA 2026 conference. Estimated price impact ≥1% as it validates a secondary pipeline asset. Expected.
Announced the issuance of USD-settled zero-coupon convertible bonds due 2027 with a principal amount of RMB 6.78 billion on 2026-05-14. The net proceeds of approximately USD 1.023 billion will be used for global capacity expansion and general corporate purposes. High importance estimated due to the significant scale of the capital raise and potential dilution scheduled.
The listing of eco-partner company Medipark on the Hong Kong Stock Exchange (ticker 7666.HK) is expected. The successful listing of a key invested and empowered partner is estimated to have a medium market impact (>=5%).
NMPA approval of the IND application for SKB118, a PD-1 x VEGF bispecific antibody for advanced solid tumors; Medium importance estimated due to potential for >5% price impact as a new clinical milestone scheduled
NMPA approval for clinical trials for SHR-3821 injection and other drugs on May 13, 2026, scheduled. Low importance is estimated as clinical trial starts have limited immediate price impact.
Board approved an A-share buyback plan on 2026-05-13 for RMB500 million to RMB1.0 billion, equal to about 0.97% to 1.94% of total shares at the price cap; no clear realized market reaction was confirmed, but the support to valuation suggests a low positive impact estimate.